# FDA approvals today

Canonical: https://sec-api.dev/fda-approvals-today

> No approvals of tracked drugs are recorded for November 16, 2026 yet. The most recent is RYZUMVI (ryzumvi, VTRS) on November 5, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Recent approvals (last 30 days)

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 5, 2026 | [RYZUMVI (ryzumvi) FDA approval](https://sec-api.dev/pdufa/ryzumvi) | VTRS | presbyopia in adults | completed, approved | "•In October, the Company announced that the FDA approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000053/exhibit991-3q26earningsrel.htm)) |
| November 5, 2026 | [MIMRYLO™ (rusfertide) FDA approval](https://sec-api.dev/pdufa/rusfertide) | PTGX | erythrocytosis in adults with polycythemia vera | completed, approved | "Protagonist announced that its partner Takeda received U.S. Food and Drug Administration (FDA) approval of MIMRYLO for the treatment of erythrocytosis in adults with polycythemia vera (PV)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926123351/tm2629043d1_ex99-1.htm)) |
| November 3, 2026 | [WELTRUZA (weltruza) FDA approval](https://sec-api.dev/pdufa/weltruza) | TEVA |  | completed, approved | "The FDA approval of WELTRUZA has further advanced our innovative portfolio, our recently announced biosimilars agreement with Samsung Bioepis has strengthened our generics powerhouse and our return to investment grade reflects the transformation of our financial position." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184326007054/exh_991.htm)) |
| October 30, 2026 | [Juvmo (tavapadon) FDA approval](https://sec-api.dev/pdufa/tavapadon) | ABBV | with Parkinson's disease | completed, approved | "•AbbVie announced the FDA approved Juvmo (tavapadon) tablets as the only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease (PD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000033/abbv-20260930xexhibit991.htm)) |
| October 30, 2026 | [KETAFREE (ketamine) FDA approval](https://sec-api.dev/pdufa/ketamine) | NRXP |  | completed, approved | "The Company will host a conference call at 8:30 a.m. ET on Friday, October 30, 2026, to discuss the FDA approval of Preservative-Free Ketamine." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1719406/000143774926034284/ex_1035048.htm)) |
| October 30, 2026 | [INOVIO PHARMACEUTICALS, INC. FDA approval](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed, approved | "INOVIO Announces FDA Accelerated Approval of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000119312526442648/d150457dex991.htm)) |
| October 30, 2026 | [Skyrizi® (risankizumab) FDA approval](https://sec-api.dev/pdufa/risankizumab) | ABBV | moderately to severely active Crohn's disease | completed, approved | "•AbbVie announced the U.S. Food and Drug Administration (FDA) approved Skyrizi (risankizumab) for subcutaneous (SC) induction in the treatment of moderately to severely active Crohn's disease (CD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000033/abbv-20260930xexhibit991.htm)) |
| October 26, 2026 | [HIBSAGO (bepirovirsen) PDUFA date](https://sec-api.dev/pdufa/bepirovirsen) | GSK |  | completed, approved | "In Q1, the US FDA accepted for priority review a New Drug Application (NDA) for bepirovirsen and set 26 October 2026 as the decision goal date." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426004051/a2755c.htm)) |
| October 24, 2026 | [Joenja® (leniolisib) PDUFA date](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed, approved | "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 24, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000033/a2026hy1pressrelease.htm)) |
| October 22, 2026 | [Pavblu (aflibercept-ayyh) FDA approval](https://sec-api.dev/pdufa/aflibercept-ayyh) | AMGN |  | completed, approved | "BLA761298 ORIG-2: submission_status AP, submission_status_date 20261022, review_priority STANDARD; sponsor_name AMGEN INC; product PAVBLU (AFLIBERCEPT-AYYH)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761298%22)) |
| October 20, 2026 | [HIBSAGO (bepirovirsen) FDA approval](https://sec-api.dev/pdufa/bepirovirsen) | GSK | chronic hepatitis B | completed, approved | "Hibsago \| bepirovirsen \| 10/20/2026 \| To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| October 20, 2026 | [AMJEVITA® (adalimumab) FDA approval](https://sec-api.dev/pdufa/adalimumab) | ALVO |  | completed, approved | "REYKJAVIK, Iceland and LONDON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a new manufacturing process for SIMLANDI® (adalimumab-ryvk), Alvotech's biosimilar to Humira® (adalimumab)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184326006704/exh_991.htm)) |
| October 19, 2026 | [Jemperli (dostarlimab) FDA approval](https://sec-api.dev/pdufa/dostarlimab) | GSK | stage II and III microsatellite instability-high | completed, approved | "GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer under the accelerated approval pathway." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426009036/a5712z.htm)) |

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "FDA approvals today." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-approvals-today

```bibtex
@misc{secapidev_fda_approvals_today_20261116,
  title        = {FDA approvals today},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-approvals-today}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_approvals_today_20261116","title":"FDA approvals today","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-approvals-today","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
